Intraoperative Use of ClearEdge Device in Breast Conserving Surgery

Description

Multi center, pivotal prospective, randomized clinical trial The proposed randomized controlled study will evaluate the benefits of adding the ClearEdge imaging device to the Standard of Care (SoC) of margins assessment in breast conserving surgeries. The study will assess whether there is an improvement in the detection of DCIS or invasive cancer involved margins by measuring whether removal at the time of primary surgical treatment can reduce the need for repeat surgeries as compared to the SoC, which does not use the device.

Conditions

Breast Cancer

Study Overview

Study Details

Study overview

Multi center, pivotal prospective, randomized clinical trial The proposed randomized controlled study will evaluate the benefits of adding the ClearEdge imaging device to the Standard of Care (SoC) of margins assessment in breast conserving surgeries. The study will assess whether there is an improvement in the detection of DCIS or invasive cancer involved margins by measuring whether removal at the time of primary surgical treatment can reduce the need for repeat surgeries as compared to the SoC, which does not use the device.

Intraoperative Use of ClearEdge Device in Breast Conserving Surgery

Intraoperative Use of ClearEdge Device in Breast Conserving Surgery

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

San Francisco

UCSF Medical Center at Mission Bay, San Francisco, California, United States, 94158

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients who are female (genotype)
  • 2. Patients aged above 18 years, inclusive
  • 3. Patients diagnosed with breast DCIS or invasive cancer recommended for lumpectomy procedure
  • 4. Patients treated with neoadjuvant endocrine therapy may be enrolled
  • 1. Patients currently receiving chemotherapy
  • 2. Patients having prior ipsilateral surgical treatment for breast cancer
  • 3. Patients who have had radiation therapy for ipsilateral breast cancer or for other malignancy that includes breast tissue in the radiation field (e.g. Hodgkin's lymphoma)
  • 4. Patients who have breast implants
  • 5. Patients who are pregnant and/or lactating
  • 6. Patients participating in other breast cancer studies involving surgical treatment to the breast in the past 6 months.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

LS BioPath,

Jasmine Wong, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco Medical Center

Study Record Dates

2024-12-31